A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter
The purpose of this study is to determine whether a combination of Sunitinib, Temozolomide
and Radiation Therapy would be effective in the treatment of newly diagnosed Glioblastoma
patients harboring tumours with unmethylated MGMT promoter.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society